Dogwood Therapeutics, Inc.DWTXEarnings & Financial Report
Dogwood Therapeutics, Inc. is a clinical-stage biotechnology company focused on researching and developing targeted therapies for rare kidney diseases, metabolic disorders, and other unmet medical needs. It collaborates with global healthcare and research partners to advance its pipeline of innovative treatment candidates for patient populations worldwide.
Revenue
$36.3K
Gross Profit
N/A
Operating Profit
$-1.5M
Net Profit
$-1.4M
Gross Margin
N/A
Operating Margin
-4068.0%
Net Margin
-3968.0%
YoY Growth
655.9%
EPS
$-0.08
Dogwood Therapeutics, Inc. Q2 FY2023 Financial Summary
Dogwood Therapeutics, Inc. reported revenue of $36.3K (up 655.9% YoY) for Q2 FY2023, with a net profit of $-1.4M (up 60.7% YoY) (-3968.0% margin).
Key Financial Metrics
| Total Revenue | $36.3K |
|---|---|
| Net Profit | $-1.4M |
| Gross Margin | N/A |
| Operating Margin | -4068.0% |
| Report Period | Q2 FY2023 |
Dogwood Therapeutics, Inc. Annual Revenue by Year
Dogwood Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $150.9K).
| Year | Annual Revenue |
|---|---|
| 2023 | $150.9K |
| 2022 | $67.5K |
Dogwood Therapeutics, Inc. Quarterly Revenue & Net Profit History
Dogwood Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2024 | $22.8K | -43.7% | $-1.3M | -5672.2% |
| Q4 FY2023 | $35.0K | -22.6% | $-1.1M | -3156.2% |
| Q3 FY2023 | $39.2K | +136.2% | $-1.2M | -3149.5% |
| Q2 FY2023 | $36.3K | +655.9% | $-1.4M | -3968.0% |
| Q1 FY2023 | $40.4K | +4361.7% | $-1.5M | -3752.5% |
| Q4 FY2022 | $45.2K | +3461.5% | $-2.0M | -4527.4% |
| Q3 FY2022 | $16.6K | +1000.4% | $-2.6M | -15511.7% |
| Q2 FY2022 | $4.8K | +221.3% | $-3.7M | -76337.5% |
Income Statement
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4804 | $16605 | $45160 | $40423 | $36313 | $39215 | $34953 | $22766 |
| YoY Growth | 221.3% | 1000.4% | 3461.5% | 4361.7% | 655.9% | 136.2% | -22.6% | -43.7% |
Balance Sheet
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $9.0M | $10.9M | $8.4M | $6.5M | $5.2M | $5.2M | $4.2M | $3.2M |
| Liabilities | $1.9M | $1.6M | $1.0M | $549290 | $520032 | $487144 | $358548 | $570083 |
| Equity | $7.1M | $9.2M | $7.3M | $6.0M | $4.7M | $4.8M | $3.8M | $2.7M |
Cash Flow
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.7M | $-2.5M | $-2.7M | $-1.7M | $-742414 | $-960454 | $-1.5M | $-937414 |